Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

@article{Navari2008FosaprepitantAN,
  title={Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting},
  author={Rudolph M Navari},
  journal={Expert Review of Anticancer Therapy},
  year={2008},
  volume={8},
  pages={1733 - 1742}
}
  • R. Navari
  • Published 1 November 2008
  • Medicine
  • Expert Review of Anticancer Therapy
Chemotherapy-induced nausea and vomiting (CINV) is a distressing and common adverse event associated with cancer treatment. Updated antiemetic guidelines were published in 2008 by the National Comprehensive Cancer Network and, in 2006, by the American Society of Clinical Oncology, which have included the use of the new and more effective antiemetic agents 5-hydroxytryptamine-3 (5-HT3) receptor antagonist and neurokinin (NK)-1 receptor antagonist. Aprepitant is a selective NK-1 receptor… 
Use of antiemetics in the prevention of chemotherapy-induced nausea and vomiting: review and focus on the Belgian situation.
TLDR
It is concluded that further improvements are still desirable, particularly in the prevention and treatment of delayed emesis, and the international guidelines currently in place for its Prevention and treatment are concluded.
Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting
TLDR
The pharmacology of NK-1 antagonists, their efficacy in clinical practice, and how they could fit into the framework of PONV management are discussed.
Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
TLDR
The crossroads of acute and delayed emesis seem to include interactions among the 5-HT3 and NK1 receptor signaling pathways and inhibitions of these interactions could lead to improved treatment of CINV.
A Randomized Controlled Pilot Study Comparing the Impact of Aprepitant and Fosaprepitant on Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecologic Cancer
TLDR
The findings from the current analysis suggest that intravenous fosaprepitant and oral aprepitant confer beneficial antiemetic prevention and theoretically afford a favorable impact on daily living, thereby potentially facilitating the completion of a patient’s clinically prescribed chemotherapy regimen.
Equivalent Dynamic Human Brain NK1‐Receptor Occupancy Following Single‐Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging
TLDR
The study illustrates the utility of PET imaging in determining central bioequivalence in a limited number of subjects and evaluates the magnitude and duration of brain NK1R occupancy over a period of 5 days after single‐dose i.v. fosaprepitant.
Neuropeptides and inflammatory bowel disease
TLDR
Although the available data suggest an important role for neuropeptides in the pathophysiology of intestinal inflammation, there does yet not appear to be a function that can be taken as established for any of these molecules.
UVR-B-induced NKR-1 Expression in Ocular Tissues is blocked by Substance P Receptor Antagonist Fosaprepitant in the Exposed as well as Unexposed Partner Eye
TLDR
The clinically approved N KR-1 receptor antagonist Fosaprepitant decreases NKR-1 protein expression effectively not only in the exposed but also in the unexposed partner eye in a UVR-B irradiation mouse model.
Chapter 28 To Market, To Market — 2008
TLDR
Among the cardiovascular and hematological NMEs launched past year, Amgen's recombinant fusion protein known as “Nplate ®” attracted significant attention due to its therapeutic novelty and represented the only first-in-class therapy of the year.
Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study
TLDR
This study demonstrated a strong relationship between depression scores and cognitive impairment, sleep quality, marital status, fosaprepitant intake, and PER2 polymorphism, while anxiety scores were correlated to cognitive impairment and insomnia severity.
Growth inhibition of formed corneal neovascularization following Fosaprepitant treatment
The aim of this study was to test the efficacy of Neurokinin‐1 Receptor (NK‐1R) antagonist −Fosaprepitant− in inducing regression of established corneal neovascularization (CNV).
...
1
2
...

References

SHOWING 1-10 OF 47 REFERENCES
Emerging drugs for chemotherapy-induced emesis
TLDR
Future studies may consider the use of palonosetron and aprepitant with current and other new agents (olanzapine, gabapentin) in moderately and highly emetogenic chemotherapy, as well as in the clinical settings of multiple-day chemotherapy and bone marrow transplantation.
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
TLDR
The neurokinin-1-receptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin and combined with granisetron plus dexamethasone improves the prevention of acute emesis.
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
  • P. Hesketh, S. Grunberg, +11 authors K. Horgan
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Compared with standard dual therapy, addition of aprepitant was generally well tolerated and provided consistently superior protection against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
TLDR
Aprepitant at clinically recommended doses may have a low potential to affect the pharmacokinetics of intravenous chemotherapeutic agents metabolized by CYP3A4.
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
TLDR
Concomitant administration of aprepitant had no clinically significant effect on the mean pharmacokinetic characteristics of either ondansetron or granisetron in these healthy subjects.
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
TLDR
A single dose of L-758,298 substantially suppressed the delayed nausea and vomiting characteristic of high dose cisplatin and also appeared to reduce acute emesis post-cisplatin, supporting the proposition that the underlying mechanism(s) of acute and delayed emesis are different.
Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
Aprepitant is a neurokinin1 receptor antagonist that, in combination with a corticosteroid and a 5‐hydroxytryptamine3 receptor antagonist, has been shown to be very effective in the prevention of
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients
TLDR
As the aprepitant antiemetic regimen has no detectable inhibitory or inductive effect on the pharmacokinetics of vinorelbine, aprepant when added to a standard antiemetics regimen consisting of ondansetron and dexamethasone can be safely combined with vinorlbine at clinically recommended doses.
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
TLDR
The authors sought to evaluate further the efficacy and tolerability of aprepitant plus standard therapy in a large clinical trial.
Lack of Effect of Aprepitant on Digoxin Pharmacokinetics in Healthy Subjects
Aprepitant is a highly selective neurokinin‐1 receptor antagonist that, in combination with a corticosteroid and a 5‐hydroxytryptamine3 (5HT3) receptor antagonist, has been shown to be efficacious in
...
1
2
3
4
5
...